Supplementary Figure S1 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461797.v1

2023-01-01

Abstract:Supplementary Figure S1. Typical staining results of immunohistochemistry.

What problem does this paper attempt to address?

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461794

2023-01-01

Abstract:Supplementary Figure S2. Overall survival of melanoma patients in relation to mTOR nonsynonymous mutations.
Supplementary Table S6 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461785

2023-01-01

Abstract:Supplementary Table S6. Statistical analysis of the effects of PI3K-AKT-mTOR inhibitors on proliferation of HEK293T cells bearing mTOR mutation.
Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461800.v1

2023-01-01

Abstract:Figure legends for Supplementary Figure S1 and Figure S2
Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Jiannong Li,Inna Smalley,Zhihua Chen,Jheng-Yu Wu,Manali S. Phadke,Jamie K. Teer,Thanh Nguyen,Florian A. Karreth,John M. Koomen,Amod A. Sarnaik,Jonathan S. Zager,Nikhil I. Khushalani,Ahmad A. Tarhini,Vernon K. Sondak,Paulo C. Rodriguez,Jane L. Messina,Y. Ann Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22486712

2023-01-01

Abstract:Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy
Supplementary Figure 3 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.
Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chi,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruifeng Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036.v1

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.
Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to Pi3k-Akt-Mtor Pathway Inhibitors

Yan Kong,Lu Si,Yi Qian Li,Xiao Wen Wu,Xiao Wei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xi Nan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.ccr-15-1110

2023-01-01

Abstract:Abstract Purpose: mTOR is a validated target in cancer. It remains to be determined whether melanoma patients bearing mTOR mutation could be selected for treatment with PI3K–AKT–mTOR pathway inhibitors. Experimental Design: A total of 412 melanoma samples were included. Gene aberrations in all exons of mTOR were detected by Sanger sequencing and confirmed by using Agilent's SureSelect Target Enrichment System. HEK293T cells stably expressing mTOR mutants were constructed by using transcription activator-like effector nucleases technique. Function of mTOR mutants and in vitro sensitivity of gain-of-function mTOR mutations to PI3K–AKT–mTOR pathway inhibitors were analyzed. Results: The overall incidence of somatic nonsynonymous mutations of mTOR was 10.4% (43/412). mTOR nonsynonymous mutations were relatively more frequent in acral (11.0%) and mucosal (14.3%) melanomas than in chronic sun-induced damage (CSD; 6.7%) and non-CSD (3.4%) melanomas. Of the 43 cases with mTOR mutations, 41 different mutations were detected, affecting 25 different exons. The median survival time for melanoma patients with mTOR nonsynonymous mutation was significantly shorter than that for patients without mTOR nonsynonymous mutation (P = 0.028). Transient expression of mTOR mutants in HEK293T cells strongly activated the mTOR–p70S6K pathway. In HEK293T cells with stable expression of H1968Y or P2213S mTOR mutants, LY294002 and AZD5363 showed higher potency than temsirolimus or BYL719 in inhibiting the PI3K–AKT–mTOR pathway and cell proliferation. Conclusions: mTOR nonsynonymous mutations are frequent in melanoma patients. mTOR nonsynonymous mutation may predict a worse prognosis of melanoma. Clinical trials with PI3K–AKT–mTOR pathway inhibitors may be beneficial for melanoma patients with specific mTOR mutations. Clin Cancer Res; 22(4); 1018–27. ©2015 AACR.
Supplementary Figure 2 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446039.v1

2023-01-01

Abstract:PDF file - 1452K, Figure S2. Genetic mutations in exon 14 of PDGFRA.
Analysis of Mtor Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.

Yan Kong,Lu Si,Yi Q. Li,Xiao W. Wu,Jie Dai,Huan Tang,Meng Ma,Zhi H. Chi,Xi N. Sheng,Chuan L. Cui,Jun Guo

DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.9049

IF: 45.3

2015-01-01

Journal of Clinical Oncology

Abstract:9049 Background: mTOR is a validated target in cancer treatment. mTOR mutations are estimated to be 2.46% of all cancers and 5.76% of cutaneous melanoma. However, mTOR mutations in other types of melanoma have not been reported. Methods: This study involved tumor samples from 412 Chinese melanoma patients, including 210 acral melanomas, 105 mucosal melanomas, 30 melanomas on skin with chronic sun-induced damage and 58 melanomas on skin without chronic sun-induced damage. Tissue samples were analyzed for mutations in all exons of mTOR gene in genomic DNA by Sanger sequencing. Mutation status was confirmed using Agilent’s sureselect target enrichment system. HEK293T cells stably expressing mutant mTOR were constructed by TALEN (Transcription Activator-like Effector Nucleases). Function of mTOR mutants in these cells and in vitro sensitivity of mTOR gain-of-function mutations to PI3K-AKT-mTOR pathway inhibitors were analyzed. Results: The overall incidence of somatic mutations within the mTOR gene was 10.4% (43/412). Increased mTOR mutations were relatively more frequent in acral (11.0%) and mucosal (14.4%) melanomas than in CSD (6.7%) and Non-CSD (3.4%) melanomas. Of the 43 cases with mTOR mutations, 41 different mutations were detected, affecting 25 different exons. Point mutations resulting in single amino acid substitutions (totaling 40 mutations detected in 43 patients) were the most common type of mTOR mutation. The median survival time for melanoma patients with mTOR mutation was significantly shorter than that for patients without mTOR mutation (P = 0.028). Transient expression of several mTOR mutants in HEK293 cells strongly activated the mTOR/p70S6K pathway. In HEK293 cells with stable expression of H1968Yor P2213S mTOR mutants, LY294002 and AZD5363 showed higher potency than Temsirolimus or BYL719 in inhibiting the mTOR/p70S6K pathway. Conclusions: These data demonstrate that mTOR mutations are more frequent in Chinese melanoma patients than in Caucasian melanoma patients. mTOR mutations is a worse prognostic factor in Chinese melanoma patients. Clinical trials with PI3K-AKT-mTOR pathway inhibitors may be beneficial for melanoma patients with mTOR mutations.
Supplementary Figure 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529654

2023-01-01

Abstract:PDF file 106K, S2215Y mTOR activates mTORC1 signaling similar to WT and mutant PI3K-p110alpha
Supplementary Figure 2 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Xiaosong Chen,Meizhong Zhao,Mingang Hao,Xueqing Sun,Jinglong Wang,Yan Mao,Lidong Zu,Junjun Liu,Yandong Shen,Jianhua Wang,Kunwei Shen

DOI: https://doi.org/10.1158/1541-7786.22510113.v1

2023-01-01

Abstract:PDF file - 471K, Growth-inhibitory effects of tamoxifen, everolimus, and various PI3K inhibitors on breast cancer cell lines.
Table S6 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Rong Zhou,Chaoji Shi,Wenjie Tao,Jiang Li,Jing Wu,Yong Han,Guizhu Yang,Ziyue Gu,Shengming Xu,Yujue Wang,Lizhen Wang,Yanan Wang,Guoyu Zhou,Chenping Zhang,Zhiyuan Zhang,Shuyang Sun

DOI: https://doi.org/10.1158/1078-0432.22475268.v1

2023-01-01

Abstract:Supplementary figures and figure legends. (Figure S1) Deregulation of genes within key affected signaling pathways in MM. (Figure S2) Validation of the somatic SNV/InDels found in POM121. (Figure S3) Copy number changes in MM. (Figure S4) Distribution of SVs and genetic events including breakage-fusion-bridges [BFBs] and chromothripsis across chromosomes among all samples. (Figure S5) Validation of SV occurring between chromosome 5 and 12 in MM023 and MM065. (Figure S6) Fine structure of BFBs and chromothripsis found in MM. (Figure S7) Comparison of lesions found in mucosal melanoma. (Figure S8) Validation of the copy number alteration of CDK4 and TERT in representative samples. (Figure S9) FISH confirming amplification and co-localization of CDK4 [12q14] and TERT [5p15]. (Figure S10) Molecular characterization of the MM PDX models and the effects of palbociclib on Rb phosphorylation in treatment-responsive PDX models. (Figure S11) Significant mutated non-coding region genes in MMs. (Figure S12) Mutation signatures found in MM.
Association of the Activation of the Mtor Pathway with Prognosis in Chinese Melanoma Patients.

Yan Kong,Lu Si,Xiao Wei Xu,Keith T. Flaherty,Zhi Hong Chi,Chuan Liang Cui,Xi Nan Sheng,Jie Dai,Long Liang,Qian Nan Zhang,Jun Guo

DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.8561

IF: 45.3

2012-01-01

Journal of Clinical Oncology

Abstract:8561 Background: mTOR is a ubiquitously expressed protein kinase and a validated target in the treatment of cancer. However, the characterization of mTOR pathway in Asian melanoma populations has not been reported. Methods: This study involved primary tumor samples from 173 melanoma patients (79 acral melanomas, 57 mucosal melanomas, 17 melanomas on skin with chronic sun-induced damage, 20 melanomas on skin without chronic sun-induced damage) in Peking University Cancer Hospital & Institute. Clinical data were collected. Immunohistochemistry assays using antibodies against pmTOR, pS6RP, p4E-BP1 and pAKT were performed on formalin-fixed, paraffin-embedded specimens. Somatic mutations within the hotspot regions of frequently mutated genes in mTOR pathway (AKT1, TSC1, PI3K genes, etc) were analyzed by PCR amplification and Sanger sequencing. Results: Among the 173 samples, 26% of the cases (45/173) demonstrated positive staining with pmTOR. Expression of pS6RP was observed in 37% (64/173) of cases. Expression of p4E-BP1 was observed in 27% (46/173) of cases. pAKT was expressed by 22% (38/173) of cases. Somatic mutations in examined genes were detected. The median survival time for patients with expression of pmTOR was significantly shorter than patients with absence of pmTOR expression (25.3 vs 62.9 months, P =0.048). In addition, statistical differences were found for ulceration rates between melanomas with or without pS6RP (64.1%vs 35.9%, P= 0.049). Moreover, the median survival time for mucosal melanoma patients with pAKT expression was significantly shorter than for patients with absence of pAKT expression (20.4 vs 52.1 months, P =0.022). Conclusions: These data demonstrate that activation of the mTOR signaling pathway carries prognostic significance in Asia patients with melanoma. Targeted therapies to mTOR pathway may offer a therapeutic benefit for these melanoma patients.
Supplementary Data from Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

Yan Kong,Lu Si,Yanyan Zhu,Xiaowei Xu,Christopher L. Corless,Keith T. Flaherty,Li,Haifu Li,Xinan Sheng,Chuanliang Cui,Zhihong Chi,Siming Li,Mei Han,Lili Mao,Aiping Lu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22442474

2023-01-01

Abstract:Supplementary Figures S1-S8; Supplementary Tables S1-S3.
Supplementary Figures 1-2, Table 1 from Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression

Keiran S.M. Smalley,Rooha Contractor,Thiennga K. Nguyen,Min Xiao,Robin Edwards,Viswanathan Muthusamy,Alastair J. King,Keith T. Flaherty,Marcus Bosenberg,Meenhard Herlyn,Katherine L. Nathanson

DOI: https://doi.org/10.1158/0008-5472.22374897

2023-01-01

Abstract:Supplementary Figures 1-2, Table 1 from Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
Supplementary Figure 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Brian C. Grabiner,Valentina Nardi,Kıvanç Birsoy,Richard Possemato,Kuang Shen,Sumi Sinha,Alexander Jordan,Andrew H. Beck,David M. Sabatini

DOI: https://doi.org/10.1158/2159-8290.22529657.v1

2023-01-01

Abstract:PDF file 85K, mTOR pathway mutations
Supplementary Figure 1 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Xiaosong Chen,Mengmeng Zhao,Mingang Hao,Xueqing Sun,Jinglong Wang,Yan Mao,Lidong Zu,Junjun Liu,Yandong Shen,Jianhua Wang,Kunwei Shen

DOI: https://doi.org/10.1158/1541-7786.22510116

2023-01-01

Abstract:PDF file - 588K, Effects of single agent of tamoxifen, everolimus, or PI3K inhibitors (LY294002 or BKM120, BEZ-235) on MCF-7 and BT474 breast cancer cell lines after 48h and 72h treatment.
Bioinformatical analysis identified significant genes in the PI3K-Akt signaling pathway relating with poor prognosis of skin cutaneous melanoma

Yingzi Zhang,Yunlan Zhang,Xuyun Hu

DOI: https://doi.org/10.1101/2020.09.08.20190280

2020-09-10

Abstract:Abstract Skin cutaneous melanoma (SKCM) is the most serious form of skin cancer and the reliable genetic prognostic biomarkers are not clear. The purpose of the present academic work was to identify reliable prognostic biomarkers and understand the underlying mechanism. Gene expression profiles of GSE31909, GSE104849 and GSE111766 were available from Gene Expression Omnibus (GEO). DEGs were collected from 13 melanoma samples and 12 melanocyte samples which were in the three profile datasets by GEO2R analysis. Gene ontology (GO) analysis and KEGG analysis were performed with the Database for Annotation, Visualization and Integrated Discovery (DAVID).We further established protein-protein interaction (PPI) and identify core genes with Search Tool for the Retrieval of Interacting Genes (STRING) and Molecular Complex Detection (MCODE) app in Cytoscape software. There were total of 63 consistently expressed genes in the three datasets, including eight up-regulated genes enriched in biological processes like osteoblast differentiation and extracellular matrix organization, and cell component like extracellular space, while 55 down-regulated genes enriched in positive regulation of gene expression, intracellular signal transduction, cell adhesion and apoptotic process. With prognostic information and expression data from UALCAN and Gene Expression Profiling Interactive Analysis (GEPIA), we identified three significant genes ( TNC, SPP1 and KIT ). After Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, all three genes were located in the PI3K-Akt Signaling Pathway. Our results provide additional genetic biomarkers for SKCM patients.
Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Yan Kong,Xinan Sheng,Xianliang Wu,Junya Yan,Meng Ma,Jihong Yu,Lu Si,Zhihong Chen,Chuanliang Cui,Jie Dai,Yiqian Li,Huan Yu,Teng Xu,Huan Tang,Bixia Tang,Lili Mao,Bin Lian,Xuan Wang,Xieqiao Yan,Siming Li,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22463072.v1

2023-01-01

Abstract:Supplementary Figure S1. Typical staining of CDK4 pathway-related proteins Supplementary Figure S2. Sensitivity of acral melanoma cells to CDK4/6 inhibitors. Supplementary Figure S3. Western blotting assays of total Rb and phosphorylated Rb (pRb) in cell lines after CDK4/6 inhibitor treatments Supplementary Figure S4. Representative images of tumor nodules after the treatments. Supplementary Figure S5. Rb inactivation status in PDX models after AT7519 and PD0332991 treatments.

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to Pi3k-Akt-Mtor Pathway Inhibitors

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Analysis of Mtor Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.

Supplementary Figure 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 2 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Table S6 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Association of the Activation of the Mtor Pathway with Prognosis in Chinese Melanoma Patients.

Supplementary Data from Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

Supplementary Figures 1-2, Table 1 from Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression

Supplementary Figure 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Figure 1 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Bioinformatical analysis identified significant genes in the PI3K-Akt signaling pathway relating with poor prognosis of skin cutaneous melanoma

Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Supplementary Figure S1 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors